← All trials
NCT04403685
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 8, 2020
- Primary completion
- Jul 8, 2020
- Completion date
- Aug 31, 2020
- First posted
- May 27, 2020
- Last posted
- May 28, 2020
- Enrollment
- 150
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Beneficência Portuguesa de Sao PauloLead sponsor
- Albert Einstein Israelite HospitalCollaborator
- Hospital Sirio-LibanesCollaborator
- Hospital Moinhos de VentoCollaborator
- Hospital do CoracaoCollaborator
- Beneficência Portuguesa de Sao PauloOverall official - principal investigator
- Beneficência Portuguesa de Sao PauloReponsible party - principal investigator
- Brazilian Clinical Research InstituteCollaborator
- Brazilian Research In Intensive Care NetworkCollaborator
- Oswaldo Cruz FoundationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.